Theriva Biologics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
TOVX$0.15-7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the year ended | ||||||
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Operating Costs and Expenses: · · | ||||||
| General and administrative | | $7,120 | | $9,858 | ||
| Research and development | | 14,311 | | 11,723 | ||
| Total Operating Costs and Expenses | | 21,431 | | 21,581 | ||
| Loss from Operations | | (21,431) | | (21,581) | ||
| Other Income: | | | ||||
| Foreign currency exhange gain (loss) | | | 3 | | | (41) |
| Interest income | | 1,439 | | 512 | ||
| Total Other Income | | | 1,442 | | | 471 |
| | | | | | | |
| Net Loss before income taxes | | | (19,989) | | | (21,110) |
| Income tax benefit | | | 1,640 | | | 1,425 |
| | | | | | | |
| Net Loss Attributable to Theriva Biologics, Inc. and Subsidiaries | | $(18,349) | | $(19,685) | ||
| | | | | | | |
| Effect of Warrant exercise price adjustment | | — | | (340) | ||
| | | | | | | |
| Net Loss Attributable to Common Stockholders | | $(18,349) | | $(20,025) | ||
| | | | ||||
| Net Loss Per Share - Basic and Dilutive | | $(1.14) | | $(1.31) | ||
| | | | ||||
| Weighted average number of shares outstanding during the period - basic and dilutive | | 16,107,014 | | 15,327,328 | ||
| | | | | | | |
| Net Loss | | | (18,349) | | | (19,685) |
| Gain (loss) on foreign currency translation | | | 711 | | | (679) |
| Total comprehensive loss | | | (17,638) | | | (20,364) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.